Results 111 to 120 of about 24,414 (214)

Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice

Journal of Lipid Research, 2007
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of a family of proteases that is thought to promote the degradation of the low density lipoprotein receptor (LDLR) through an as yet undefined mechanism.
Mark J. Graham, Kristina M. Lemonidis, Charles P. Whipple, Amuthakannan Subramaniam, Brett P. Monia, Stanley T. Crooke, Rosanne M. Crooke   +6 more
doaj   +1 more source

Letter to the Editor in Response to “A novel index for diagnosis of type 2 diabetes mellitus: Cholesterol, high density lipoprotein, and glucose (CHG) index”

Journal of Diabetes Investigation, EarlyView.
Ying Li, Lei Jin
wiley   +1 more source

Treg cells retain stable lineage commitment during pregnancy in mice after late gestation inflammatory challenge

Immunology &Cell Biology, Volume 104, Issue 3, Page 276-311, March 2026.
In this study, we used Foxp3‐fatemapping mice to examine the cell lineage stability of Treg cells in pregnancy. Ex‐Foxp3 cells were identified in gestational tissues. However, Treg cells retained lineage stability with no increased ex‐Foxp3 generation, regardless of inflammatory challenges that induce preterm birth.
Kerrie L Foyle, Ella S Green, Jessie R Walker‐Rogers, Ha M Tran, David M Olson, Lachlan M Moldenhauer, Sarah A Robertson   +6 more
wiley   +1 more source

Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor).

Arteriosclerosis, Thrombosis and Vascular Biology, 2019
OBJECTIVE PCSK9 (proprotein convertase subtilisin-kexin 9) enhances the degradation of the LDLR (low-density lipoprotein receptor) in endosomes/lysosomes.
Ali Ben Djoudi Ouadda, M. Gauthier, Delia Susan-Resiga, E. Girard, R. Essalmani, M. Black, J. Marcinkiewicz, D. Forget, J. Hamelin, A. Evagelidis, Kévin Ly, R. Day, L. Galarneau, F. Corbin, B. Coulombe, A. Çaku, V. Tagliabracci, N. Seidah   +17 more
semanticscholar   +1 more source

A short review of proprotein convertase subtilisin/kexin type 9 inhibitors

Reviews in Cardiovascular Medicine, 2019
Cardiovascular disease is the leading cause of morbidity and mortality globally, as estimated by the World Health Organization, where in 2016, 15.2 million deaths were attributed to ischemic heart disease and stroke. It is therefore essential to try to reduce the incidence of Cardiovascular disease by controlling modifiable risk factors. One such major
openaire   +2 more sources

Proprotein convertase subtilisin/kexin type 9 in patients with systemic sclerosis.

Clinical and experimental rheumatology, 2020
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a serine protease that regulates cholesterol metabolism through low-density lipoprotein receptor degradation, and which has been linked to cardiovascular risk. The purpose of the present study was to examine whether PCSK9 serum levels are disrupted in patients with systemic sclerosis (SS ...
Ferraz Amaro, Iván, Delgado Frías, Esmeralda, Hernández Hernández, Vanessa, Sánchez Pérez, Hiurma, Armas Rillo, Laura de, García Dopico, José Antonio, Díaz González, Federico   +6 more
openaire   +2 more sources

Phenotypic homozygous familial hypercholesterolemia successfully treated with proprotein convertase subtilisin/kexin type 9 inhibitors

Clinical Case Reports
Key Clinical Message Recent data reveal phenotypic HoFH patients may be responsive to PCSK9 inhibitors, challenging prior assumptions. Genetic testing advancements now more accurately forecast patient responses to these therapies, improving treatment ...
Ryosuke Tani, Keiji Matsunaga, Yuta Toda, Tomoko Inoue, Hai Ying Fu, Tetsuo Minamino   +5 more
doaj   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9): The Multifaceted Biology, Diseases, and Pharmaceutical Interventions

MedComm
Ischemic stroke remains a leading cause of global disability and death. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have emerged as potent lipid‐lowering agents with expanding therapeutic potential.
Jia Kuang, Lei Hao, Meibiao Zhang, Zhao Yang   +3 more
doaj   +1 more source

Proprotein convertase subtilisin/kexin type 9 and apelin in fibromyalgia syndrome

Archives of Rheumatology
Objectives: This study aimed to investigate the potential roles of proprotein convertase subtilisin/ kexin type 9 (PCSK9) and apelin in the etiology of fibromyalgia syndrome (FS). Patients and methods: The retrospective study was conducted between May 2022 and February 2023.
Pihtili Taş, Nevsun, Aydogan Baykara, Rabia, Kamanli, Ayhan, Gürbüz, Ali, Cure, Erkan, Cumhur Cüre, Medine, Erdem, Mehmet, Tasar Yildirim, Tugce   +7 more
openaire   +2 more sources

Hepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR/GLP‐1R agonist survodutide in mice

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 2437-2442, March 2026.
Fen Long, Tenagne D. Challa, Vissarion Efthymiou, Manuel Klug, Thomas Klein, Heike Neubauer, Christian Wolfrum, Carla Horvath   +7 more
wiley   +1 more source